Nerve growth factor rapidly increases muscarinic tone in mouse medial septum/diagonal band of Broca.
Nerve growth factor (NGF) has been implicated in maintaining and regulating normal functioning of the septohippocampal pathway. However, many aspects of its physiological actions and the underlying mechanisms await elucidation. In this study, we investigated the effect of acute NGF exposure on neurons in the mouse medial septum/diagonal band of Broca (MS/DB), focusing on the cholinergic neurons and the subpopulation of noncholinergic neurons that were identified to be putatively GABAergic. We report that MS/DB neurons in a thin slice preparation, when exposed to NGF via bath perfusion, rapidly and indiscriminately increased the rate of spontaneous firing in all MS/DB neurons. However, focal application of NGF to individual MS/DB neurons increased spontaneous firing in cholinergic, but not in the noncholinergic, subpopulation. The NGF-induced effect on cholinergic neurons was direct, requiring activation and signaling via TrkA receptors, which were immunohistochemically localized to the cholinergic neurons in the MS/DB. TrkA receptors were absent in putative GABAergic MS/DB neurons, and blockade of TrkA signaling in these and other noncholinergic neurons had no effect on their firing activity after exposure to NGF. Conversely, methyl scopolamine, blocked the increased firing activity of noncholinergic neurons during bath perfusion of NGF. We propose a cell type-specific mode of action for NGF in the MS/DB. The neurotrophin directly enhances cholinergic neuronal activity in the MS/DB through TrkA-mediated signaling, increasing acetylcholine release and, thus, muscarinic tone. This increase in muscarinic tone, in turn, results in heightened firing activity in noncholinergic MS/DB neurons.
Wu
Chia-wen K
CW
Center for Aging and Developmental Biology, Department of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, New York 14642, USA.
Yeh
Hermes H
HH
D000200:Action Potentials / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects; D000818:Animals; D000831:Animals, Newborn; D015153:Blotting, Western / Q000379:methods; D064032:Calbindin 2; D064026:Calbindins; D002227:Carbazoles / Q000494:pharmacology; D002795:Choline O-Acetyltransferase / Q000378:metabolism; D002800:Cholinesterase Inhibitors / Q000494:pharmacology; D020667:Diagonal Band of Broca / Q000166:cytology*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004558:Electric Stimulation / Q000379:methods; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005455:Fluorescent Antibody Technique / Q000379:methods; D066298:In Vitro Techniques; D026121:Indole Alkaloids; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009116:Muscarine / Q000378:metabolism*; D018727:Muscarinic Antagonists / Q000494:pharmacology; D009388:Neostigmine / Q000494:pharmacology; D009414:Nerve Growth Factors / Q000494:pharmacology*; D009474:Neurons / Q000187:drug effects*; D010320:Parvalbumins / Q000378:metabolism; D018408:Patch-Clamp Techniques / Q000379:methods; D020800:Receptor, Nerve Growth Factor / Q000172:deficiency; D020917:Receptor, trkA / Q000378:metabolism; D020813:Receptor, trkB / Q000378:metabolism; D064030:S100 Calcium Binding Protein G / Q000378:metabolism; D012601:Scopolamine / Q000494:pharmacology; D020665:Septum of Brain / Q000166:cytology*; D013997:Time Factors
D064032:Calbindin 2; D064026:Calbindins; D002227:Carbazoles; D002800:Cholinesterase Inhibitors; D004791:Enzyme Inhibitors; D026121:Indole Alkaloids; D018727:Muscarinic Antagonists; D009414:Nerve Growth Factors; D010320:Parvalbumins; D020800:Receptor, Nerve Growth Factor; D064030:S100 Calcium Binding Protein G; D009388:Neostigmine; D009116:Muscarine; C049985:staurosporine aglycone; D012601:Scopolamine; D002795:Choline O-Acetyltransferase; D020917:Receptor, trkA; D020813:Receptor, trkB